A recent Journal of Clinical Medicine study investigates the efficacy of oral semaglutide in patients with type 2 diabetes (T2D). Study: Oral Semaglutide in Routine Clinical Practice: Characteristics of People with Type 2 Diabetes Started on the Drug and Changes in Their Clinical Parameters after 24 Weeks of Treatment. Image Credit: Andrei_R / Shutterstock.
com Semaglutide, the first oral antidiabetic medicine for T2D, is a unique glucagon-like peptide-1 receptor agonist (GLP-1RA) that can control the glycemic index and reduce body weight (BW). In addition to its efficacy, multiple clinical trials have confirmed the safety profile of semaglutide. The PIONEER program was conducted to determine the effectiveness of oral semaglutide in patients at different stages of diabetes.
Depending on the stage of diabetes, patients received either monotherapy or multiple doses of oral glucose-lowering agents. Based on the findings of the PIONEER program, the United States Food and Drug Administration (FDA) supported the safety and efficacy of oral semaglutide in 2019, followed by approval from the European Medicines Agency (EMA) in 2020. According to the American and European guidelines for T2D management, oral semaglutide has beneficial cardiovascular effects and is recommended for T2D patients, particularly those at high or very high risk of cardiovascular diseases (CVD), regardless of glycated hemoglobin (HbA1c) levels.
Although the findings of the PIONEER study were promising, additiona.
